Regular ArticleThe fibronectin binding domain of the Sfb protein adhesin of Streptococcus pyogenes occurs in many group A streptococci and does not cross-react with heart myosin
References (0)
Cited by (49)
Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection
2017, Nanomedicine: Nanotechnology, Biology, and MedicineCitation Excerpt :Hence, mice immunized with J14-dT co-administered with CTB as adjuvant showed 70% survival when challenged with a homologous GAS M1 strain, whereas the protection level of J14-specific antibodies against heterologous strains was slightly reduced compared to J14 sequence variants.15 In contrast, the sequences encompassed by the FNBR peptides seem to be almost 100% conserved.16,18,48,60 This strongly argues for the bivalent vaccine formulation.
Streptococcus Group A Vaccines
2017, Plotkin's VaccinesStreptococcus group A vaccines
2012, Vaccines: Sixth EditionStreptococcus group A vaccines
2008, VaccinesEnhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation
2007, VaccineCitation Excerpt :Apart from the M protein, other S. pyogenes antigens have been considered as vaccine candidates, such as fibronectin-binding proteins, including fibronectin-binding protein I (SfbI) [18–20], which plays a major role in bacterial attachment, colonisation and invasion [15–17,33–39], and impairs host clearance mechanisms by interacting with IgG [40,41]. The functional domains of the SfbI protein are highly conserved and it is expressed by a large number of clinical isolates from patients affected with different forms of disease, who live in different geographic areas [42,43]. Therefore, the SfbI protein is an ideal candidate to target in a multi-component vaccine formulation.